Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have been given an average recommendation of "Buy" by the eight brokerages that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $12.67.

A number of research firms have issued reports on IMUX. StockNews.com raised shares of Immunic from a "sell" rating to a "hold" rating in a research report on Friday, January 31st. D. Boral Capital reissued a "buy" rating and set a $17.00 target price on shares of Immunic in a report on Tuesday, January 7th. Finally, HC Wainwright initiated coverage on shares of Immunic in a research report on Monday, November 25th. They set a "buy" rating and a $10.00 target price for the company.

Insider Activity at Immunic

In other Immunic news, Director Richard Alan Rudick acquired 87,300 shares of the company's stock in a transaction on Tuesday, November 12th. The shares were bought at an average cost of $1.15 per share, with a total value of $100,395.00. Following the completion of the acquisition, the director now owns 87,300 shares in the company, valued at approximately $100,395. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new position in Immunic during the third quarter worth $50,000. HB Wealth Management LLC purchased a new stake in shares of Immunic during the fourth quarter worth about $81,000. Jane Street Group LLC lifted its stake in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock valued at $116,000 after buying an additional 38,553 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock valued at $169,000 after buying an additional 42,383 shares in the last quarter. Finally, State Street Corp boosted its holdings in Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company's stock worth $276,000 after buying an additional 11,642 shares during the last quarter. Hedge funds and other institutional investors own 51.82% of the company's stock.

Immunic Stock Performance

IMUX stock traded down $0.02 during midday trading on Thursday, reaching $0.96. The stock had a trading volume of 424,888 shares, compared to its average volume of 992,769. The firm has a fifty day simple moving average of $1.07 and a two-hundred day simple moving average of $1.28. Immunic has a 52-week low of $0.92 and a 52-week high of $2.11. The stock has a market cap of $86.54 million, a PE ratio of -0.78 and a beta of 1.87.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). During the same period in the previous year, the firm posted ($0.51) earnings per share. On average, sell-side analysts predict that Immunic will post -0.94 EPS for the current fiscal year.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.